Search research articles
Contact Us
Filters
Showing results (91-100 of 111) with videos related to
Page
of 12
Sort By:
Journal of Chemotherapy (Florence, Italy)
|
December 19, 2025
The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study
Bilgeşah Kılıçtaş, Murat Araz, Ahmet Oruç, et al.
JAMA Network Open
|
February 3, 2026
Development of a Health-Related Quality of Life Tool for Adolescents and Young Adults With Cancer
Samantha Claire Sodergren, Olga Husson, Silvie Janssen, et al.
European Urology Focus
|
October 3, 2020
Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences
Deniz Tural, Ömer Fatih Ölmez, Ahmet Taner Sümbül, et al.
Scientific Reports
|
January 25, 2025
Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study
Nargiz Majidova, Hacı Arak, Faruk Recep Ozalp, et al.
Breast Cancer Research and Treatment
|
August 9, 2024
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study
İsmail Beypınar, Hacer Demir, Şendağ Yaslıkaya, et al.
Scientific Reports
|
March 19, 2025
Author Correction: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
Neslihan Özyurt, Ali Alkan, Burcu Gülbağcı, et al.
Scientific Reports
|
April 3, 2026
Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
Yasin Sezgin, Oğur Karhan, Mehmet Naci Aldemir, et al.
Frontiers in Pharmacology
|
August 13, 2016
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future
Winnie de Bruijn, Cristina Ibáñez, Pia Frisk, et al.
Scientific Reports
|
October 9, 2024
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
Neslihan Özyurt, Ali Alkan, Burcu Gülbağcı, et al.
Scientific Reports
|
April 5, 2025
Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
Yasin Sezgin, Oğur Karhan, Mehmet Naci Aldemir, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 111) with videos related to
Sort By:
Page
of 12
Journal of Chemotherapy (Florence, Italy)
|
December 19, 2025
The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study
Bilgeşah Kılıçtaş, Murat Araz, Ahmet Oruç, et al.
JAMA Network Open
|
February 3, 2026
Development of a Health-Related Quality of Life Tool for Adolescents and Young Adults With Cancer
Samantha Claire Sodergren, Olga Husson, Silvie Janssen, et al.
European Urology Focus
|
October 3, 2020
Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences
Deniz Tural, Ömer Fatih Ölmez, Ahmet Taner Sümbül, et al.
Scientific Reports
|
January 25, 2025
Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study
Nargiz Majidova, Hacı Arak, Faruk Recep Ozalp, et al.
Breast Cancer Research and Treatment
|
August 9, 2024
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study
İsmail Beypınar, Hacer Demir, Şendağ Yaslıkaya, et al.
Scientific Reports
|
March 19, 2025
Author Correction: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
Neslihan Özyurt, Ali Alkan, Burcu Gülbağcı, et al.
Scientific Reports
|
April 3, 2026
Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
Yasin Sezgin, Oğur Karhan, Mehmet Naci Aldemir, et al.
Frontiers in Pharmacology
|
August 13, 2016
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future
Winnie de Bruijn, Cristina Ibáñez, Pia Frisk, et al.
Scientific Reports
|
October 9, 2024
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
Neslihan Özyurt, Ali Alkan, Burcu Gülbağcı, et al.
Scientific Reports
|
April 5, 2025
Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
Yasin Sezgin, Oğur Karhan, Mehmet Naci Aldemir, et al.
Page
of 12